triazoles has been researched along with paroxetine in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (45.16) | 18.2507 |
| 2000's | 13 (41.94) | 29.6817 |
| 2010's | 3 (9.68) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Preskorn, SH | 1 |
| Abed, RT; Ascher, A; Baldwin, DS; Buckingham, SA; Cox, J; Hawley, CJ; Maragakis, BP; Pover, GH | 1 |
| Attenburrow, ME; Cowen, PJ; Pearson, G; Sargent, P; Sharpley, AL; Williamson, DJ | 1 |
| Bryant, SG | 1 |
| Castañeda, R; Levy, R; Sussman, N; Westreich, LM | 1 |
| Blew, PG; John, L; Perreault, MM; Tao, T | 1 |
| Cowen, PJ; Odontiadis, J; Pearson, G; Sargent, P; Williamson, DJ | 1 |
| Peak, DA | 1 |
| Campo, JV; Perel, JM; Smith, C | 1 |
| Anand, VS; Dewan, MJ | 1 |
| Cho, R; Kapur, S; Kennedy, S; Meyer, JH | 1 |
| Farvolden, P; Mancini, C; Oakman, JM; Van Ameringen, M | 1 |
| Davidson, JR | 1 |
| Dunn, NR; Freemantle, SN; Mackay, FR; Mann, RD; Martin, RM; Pearce, GL | 1 |
| Court, MH; Duan, SX; Greenblatt, DJ; Hesse, LM; Shader, RI; Venkatakrishnan, K; von Moltke, LL | 1 |
| Olivier, B; Waldinger, MD; Zwinderman, AH | 1 |
| Baruch, Y; Chelben, J; Lustig, M; Strous, RD | 1 |
| Birk, KL; De Puy, ME; Fisher, A; Goldberg, MR; Lowry, RC; Musson, DG; Shadle, CR | 1 |
| Baldwin, DS; Hawley, CJ; Mellors, K | 1 |
| Argyropoulos, SV; Bell, CJ; Edwards, C; Hicks, JA; Nash, JR; Nutt, DJ; Rich, AS; Wilson, SJ | 1 |
| Kenemans, JL; Trooster, S; van Laar, MW; van Megen, HJ; Verbaten, MN; Volkerts, ER | 1 |
| Argyropoulos, SV; Bell, CJ; Hicks, JA; Nash, JR; Nutt, DJ; Rich, AS; Wilson, SJ | 1 |
| Baker, B; Baldini-Rossi, N; Hollander, E; Pallanti, S; Sood, E | 1 |
| Blier, P; de Montigny, C; Debonnel, G; Hébert, C; Lavoie, N; Saint-André, E | 1 |
| Kelly, BD | 1 |
| Kalgutkar, AS; Obach, RS; Soglia, JR; Zhao, SX | 1 |
| Argyropoulos, SV; Bell, CJ; Hicks, JA; Nash, JR; Nutt, DJ; Rich, AS; Wilson, S | 1 |
| Gehlert, DR; Iyengar, S; Kielbasa, W; Marek, G; Mozley, D; Peng, X; Tauscher, J; Vandenhende, F | 1 |
| Aubry, JM; Bertschy, G; Bondolfi, G; Gex-Fabry, M; Kosel, M; Malafosse, A; Perroud, N; Uher, R | 1 |
| Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X | 1 |
| Krishnamurthy, S; Prajapati, SK | 1 |
5 review(s) available for triazoles and paroxetine
| Article | Year |
|---|---|
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Design; Drug Tolerance; Drugs, Investigational; Fluoxetine; Humans; Imipramine; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1995 |
Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Fluoxetine; Follow-Up Studies; Humans; Monoamine Oxidase Inhibitors; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Stress Disorders, Post-Traumatic; Treatment Outcome; Triazoles | 2000 |
Correlation of subjective and objective sleep measurements at different stages of the treatment of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Humans; Male; Paroxetine; Piperazines; Polysomnography; Sleep; Sleep Stages; Triazoles | 2003 |
Pharmacological treatments of pathological gambling.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Fluvoxamine; Gambling; Humans; Naltrexone; Outcome Assessment, Health Care; Paroxetine; Piperazines; Research Design; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Triazoles | 2005 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
12 trial(s) available for triazoles and paroxetine
| Article | Year |
|---|---|
A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Recurrence; Severity of Illness Index; Treatment Outcome; Triazoles | 1996 |
The effects of paroxetine and nefazodone on sleep: a placebo controlled trial.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Double-Blind Method; Electroencephalography; Humans; Male; Middle Aged; Paroxetine; Piperazines; Polysomnography; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep, REM; Triazoles | 1996 |
Effect of paroxetine and nefazodone on 5-HT1A receptor sensitivity.
Topics: Adult; Antidepressive Agents, Second-Generation; Blood Platelets; Double-Blind Method; Humans; Hydrocortisone; Hypothermia; Male; Middle Aged; Paroxetine; Piperazines; Pyrimidines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Receptor Agonists; Triazoles | 1997 |
Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Double-Blind Method; Ejaculation; Humans; Male; Middle Aged; Paroxetine; Piperazines; Placebos; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles | 2001 |
Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine.
Topics: Adult; Affect; Analysis of Variance; Area Under Curve; Blood Pressure; Body Temperature; Confidence Intervals; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Heart Rate; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Statistics, Nonparametric; Triazoles; Tryptamines | 1999 |
A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Long-Term Care; Male; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Recurrence; Treatment Outcome; Triazoles | 2001 |
Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Outpatients; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep, REM; Triazoles | 2002 |
Differential effects of amitriptyline, nefazodone and paroxetine on performance and brain indices of visual selective attention and working memory.
Topics: Adult; Amitriptyline; Antidepressive Agents; Attention; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Electrooculography; Evoked Potentials; Female; Humans; Male; Memory; Neuropsychological Tests; Paroxetine; Piperazines; Reaction Time; Task Performance and Analysis; Triazoles | 2002 |
Correlation of subjective and objective sleep measurements at different stages of the treatment of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Humans; Male; Paroxetine; Piperazines; Polysomnography; Sleep; Sleep Stages; Triazoles | 2003 |
Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Blood Platelets; Blood Pressure; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Piperazines; Reference Values; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Time Factors; Triazoles; Tyramine; Venlafaxine Hydrochloride | 2007 |
Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone.
Topics: Adult; Affect; Algorithms; Antidepressive Agents, Second-Generation; Delta Rhythm; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Monitoring, Ambulatory; Paroxetine; Piperazines; Signal Processing, Computer-Assisted; Sleep; Sleep, REM; Treatment Outcome; Triazoles | 2009 |
Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder.
Topics: Adult; Animals; Anti-Anxiety Agents; Anxiety Disorders; Brain; Dose-Response Relationship, Drug; Gerbillinae; Humans; Male; Neurokinin-1 Receptor Antagonists; Paroxetine; Peptide Fragments; Pyridines; Radioligand Assay; Radionuclide Imaging; Receptors, Neurokinin-1; Stereotyped Behavior; Substance P; Treatment Outcome; Triazoles | 2010 |
15 other study(ies) available for triazoles and paroxetine
| Article | Year |
|---|---|
Reassessment of nefazodone.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Humans; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles | 1996 |
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Paroxetine; Piperazines; Recurrence; Serotonin Agents; Substance-Related Disorders; Triazoles; Venlafaxine Hydrochloride | 1996 |
Serotonin syndrome associated with nefazodone and paroxetine.
Topics: Antidepressive Agents, Second-Generation; Coma; Drug Synergism; Female; Humans; Hyponatremia; Middle Aged; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Syndrome; Triazoles | 1997 |
Toxic effects of nefazodone.
Topics: Antidepressive Agents, Second-Generation; Drug Interactions; Humans; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin; Syndrome; Triazoles | 1997 |
Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Administration Schedule; Drug Interactions; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Paroxetine; Piperazines; Tacrolimus; Triazoles | 1998 |
Evaluating the tolerability of the newer antidepressants.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delayed-Action Preparations; Drug Information Services; Fluvoxamine; Gastrointestinal Diseases; Guidelines as Topic; Humans; Incidence; Paroxetine; Piperazines; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Triazoles; United States; United States Agency for Healthcare Research and Quality; Venlafaxine Hydrochloride | 1999 |
The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Binding, Competitive; Female; Fluorine Radioisotopes; Humans; Male; Paroxetine; Piperazines; Pyrimidinones; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Tomography, Emission-Computed; Triazoles | 1999 |
Serotonergic agents in the treatment of social phobia in children and adolescents: a case series.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Female; Humans; Male; Paroxetine; Phobic Disorders; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Triazoles | 1999 |
Newer antidepressants: a comparison of tolerability in general practice.
Topics: Adult; Aged; Antidepressive Agents; Cohort Studies; Cyclohexanols; Depressive Disorder; Family Practice; Female; Fluoxetine; Humans; Male; Middle Aged; Moclobemide; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1999 |
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Topics: Antibodies; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Biotransformation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Isoenzymes; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Paroxetine; Piperazines; Sertraline; Triazoles | 2000 |
Remission of SSRI-induced akathisia after switch to nefazodone.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Humans; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles | 2001 |
Do new-generation antidepressants work?
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; Piperazines; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2008 |
Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose.
Topics: Acetaminophen; Binding Sites; Buspirone; Carbamazepine; Diclofenac; Diphenhydramine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hepatocytes; Humans; Indomethacin; Meloxicam; Microsomes, Liver; Molecular Structure; Paroxetine; Piperazines; Propranolol; Raloxifene Hydrochloride; Simvastatin; Structure-Activity Relationship; Thiazines; Thiazoles; Ticrynafen; Toxicity Tests; Triazoles | 2008 |
Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clomipramine; Cyclohexanols; Depressive Disorder; Female; Genetic Association Studies; Humans; Male; Middle Aged; Paroxetine; Piperazines; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT1B; Severity of Illness Index; Suicidal Ideation; Tacrolimus Binding Proteins; Triazoles; Venlafaxine Hydrochloride; Young Adult | 2011 |
Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses.
Topics: Amygdala; Animals; Azepines; Corticosterone; Disease Models, Animal; Male; Orexin Receptor Antagonists; Orexins; Paroxetine; Rats; Rats, Wistar; Receptors, Corticotropin-Releasing Hormone; Selective Serotonin Reuptake Inhibitors; Serotonin; Stress Disorders, Post-Traumatic; Triazoles | 2021 |